Schott Pharma's Brighter Prospects After Strong Q2 Results
Pharmaceutical company, Schott, maintains a positive outlook toward the upcoming future. - Pharmaceutical company Schott Pharma remains hopeful for the future.
Schott Pharma, the pharmaceutical packaging powerhouse based in Mainz, is feeling pretty chipper about its future as it reports a fantastic Q2 and solid H1 in 2025. According to CEO Andreas Reisse and CFO Almuth Steinkühler, the company's still on track to hit its full-year forecast.
This badass company cranks out syringes, polymer syringes, and sterilized glass vials for various medications. They're also the go-to for those fancy vials used in new cancer treatments that zip in on tumors like a heat-seeking missile. For our beloved Covid vaccines, Schott Pharma produces sweet, polymer syringes that can endure that icy-cold freezer treatment.
The main aim here is to snag high single-digit currency-adjusted revenue growth. Previously, ol' Reisse mentioned a boost in operating profit for the entire year (till end of September)—without dropping a specific figure, of course.
In Q2, Schott Pharma skyrocketed its revenue by 8% year-over-year to a cool €252 million. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) jumped by 63% to €72 million. Net income stood firm at €38.6 million, compared to €25.2 million in the previous year. The company attributes this positive development to the enduring demand for glass syringes and other nifty factors.
In the first half, revenue shot up by more than 15% to €482 million. Net income was €67.6 million. In the first half of 2024, net income was a little higher at €69.7 million.
- Pharma
- Mainz
- Quarter
Here's a quick recap: Schott Pharma scored big in Q2 2025 with a 8% yoy revenue increase, a 63% leap in EBITDA, and a net income jump of 54%. This all happened while beating pre-quarter consensus estimates by a country mile. High-value solutions represented 56% of revenues in Q2, helping cool the margins.
Despite a sluggish start in Q1 and ongoing market uncertainties, Schott Pharma is bullish about its 2025 prospects, projecting:
- Revenue growth in the high single digits.
- EBITDA margin close to last year's level.
- Operating sales growth to remain robust, influenced by strong demand trends and efficiencies.
And, here's another tidbit—a more frugal investment approach means the company's revised capital expenditure forecast for 2025 now ranges from €140-160 million, down from an earlier estimate of €160-190 million.
Then there's the management commentary, which goes a little something like this:
- CEO Andreas Reisse emphasized the robust momentum in the pharmaceutical industry, expressing optimism about achieving financial targets and noting increased demand and expansion plans.
- CFO Dr. Almuth Steinkühler outlined how cost savings and higher demand for high-value solutions fueled Q2's profitability, underscoring stable growth prospects.
All in all, Schott Pharma rocked Q2 2025 with a double-digit currency-adjusted revenue increase, a beefy EBITDA margin expansion, and a hefty net income boost. This performance reaffirms the company's hopes for its full-year financial objectives, despite some caution and external uncertainties.
- Schott Pharma's successful Q2 performance in 2025, with a 8% increase in revenue and a 63% jump in EBITDA, emphasizes the potential for investing in their business, given their strong financial standing and the robust momentum in the pharmaceutical industry.
- As Schott Pharma gears up for the rest of 2025, their community policy could include vocational training programs to strengthen their workforce, given the boost in operating profit and the increased demand for high-value solutions in the pharmaceutical industry.
